VIDA Insights

VIDA

VIDA Insights™ is a lung intelligence solution providing quantitative data and visualizations. VIDA’s biomarkers measure lung destruction, inflammation, function and more, to aid the detection, diagnosis, treatment and tracking of all major lung diseases, including COPD, ILD and now COVID-19.

Information source: Vendor
Last updated: February 28, 2020

General Information

General
Product name	VIDA Insights
Company	VIDA
Subspeciality	Chest
Modality	CT
Disease targeted	COPD, interstitial lung disease (ILD), emphysema, COVID-19
Key-features	Lung disease biomarkers, lung (lobe) volume quantification, scan suitability quality check, Hyperion View (tMPR), low density tissue quantification by lobe, high density tissue quantification by lobe, trachea analysis and quanitification
Suggested use	Before: stratifying reading process (non, single, double read) During: perception aid (prompting all abnormalities/results/heatmaps), report suggestion

Technical Specifications

Data characteristics
Population	All Chest CT scans
Input	Non-contrast
Input format	DICOM
Output	Quantified Values, Novel Visualizations, Quick Flag Diagrams
Output format	DICOM SC
Technology
Integration	Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform
Deployment	Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based
Trigger for analysis	Automatically, right after the image acquisition
Processing time	1 - 10 minutes

Regulatory

Certification
CE	Certified, Class IIa , MDD
FDA	510(k) cleared , Class II
Intended Use Statements
Intended use (according to CE)	The design and manufacture of post processing software utilised in the diagnosis and documentation of pulmonary and smoking related diseases via datasets acquired from various medical modalities.

Market

Market presence
On market since	12-2019
Distribution channels	Nuance PIN, Eureka Clinical AI, TeraRecon, IBM Watson Health, Blackford, Intelerad, Calantic
Countries present (clinical, non-research use)
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing
Pricing model	Subscription
Based on	Total imaging volume

Evidence

Evidence
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers	Relationships Between Airflow Obstruction and Quantitative CT Measurements of Emphysema, Air Trapping, and Airways in Subjects With and Without Chronic Obstructive Pulmonary Disease (read) Quantitative computed tomography of the lungs and airways in healthy nonsmoking adults (read) Total Airway Count on Computed Tomography and the Risk of Chronic Obstructive Pulmonary Disease Progression. Findings from a Population-based Study (read) Quantitative CT of Interstitial Lung Disease (read) SPIROMICS Protocol for Multicenter Quantitative Computed Tomography to Phenotype the Lungs (read)